Study reveals new way to target HER2-negative metastatic breast cancer

Study reveals new way to target HER2-negative metastatic breast cancer

A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target. A research team led by Karolina Palucka, M.D., Ph.D., a professor at The Jackson Laboratory , has collaborated with researchers at The Baylor Institute for Immunology Research to show that IL1b, a member of the interleukin 1 family of cytokines drives the inflammation often found in cancer, and appears as an "IL1 signature" in women with HER2-negative metastatic breast cancer .

from Biotech News